Pioneering the Future of Cancer Treatment
Xelcis Bio™ is reimagining chemotherapeutic delivery, precisely targeting cancer cells with the intention of reducing toxic side effects through innovative pH-responsive nanoparticle technology. We founded the company to transform cancer therapy through our proprietary *TRIDENT™ delivery platform. Our versatile delivery system is designed to revolutionize targeted therapeutics across multiple modalities, from conventional small molecules to cutting-edge nanobodies and nanobody-drug conjugates.
Xelcis Bio™ is accelerating development of next-generation targeted cancer therapeutics to improve cancer care for patients worldwide
About Us
Leading the Future of Targeted Cancer Therapy
Xelcis Bio™ is pioneering a new era in targeted cancer therapeutics through our proprietary TRIDENT™ delivery platform. For our lead program, we combine cutting-edge nanoparticle technology with chemotherapy to create precisely targeted therapies that enhance effectiveness while reducing side effects. At Xelcis Bio™, we're not just improving existing treatments —we're transforming the way cancer care is delivered, with the goal of better outcomes and improved quality of life for patients worldwide.
*TRIDENT™: Tumor Recognition Integrated Drug Engagement Nanosystem Technology
Our Technology
TRIDENT™ - Smart Drug Delivery for Cancer Treatment
Targeted Delivery
TRIDENT™ 3-in-1 delivery platform is designed to enhance therapeutic delivery to tumors.
TRIDENT™ Drug Activation
Desigend to activate the therapeutic payload in the tumor microenvironment, minimizing exposure to healthy tissues.
FDA 505(b)(2) Regulatory Pathway
Speed up approval by leveraging existing safety and efficacy data, reducing costs and time to market.
Lead Candidate - Targeted Doxorubicin
Xelcis initial focus – Repurpose generic doxorubicin for targeted delivery using our proprietary delivery platform
Why Choose Us
Innovating for Better Cancer Treatment– Today and Tomorrow
We’re revolutionizing cancer treatment with cutting-edge targeted delivery technology, faster development, and a patient-first approach. For investors, it’s a groundbreaking opportunity. For patients, it’s hope for a healthier future.
Proven Leadership
The leadership team has experience and expertise in oncology drug delivery, clinical development and commercializatiion.
Innovative Technology
Our first technology combines a proprietary delivery system with chemotherapy to boost efficacy and reduce toxic side effects.
Accelerated Development
Using the FDA’s 505(b)(2) pathway, we're able to speed up our development efforts, lowering our overall costs to gain market approval.
Comprehensive IP Protection
Our robust patent portfolio protects our technology, ensuring long-term market exclusivity.
Market Potential
We’re addressing a $31B global chemotherapy market growing at 12% annually, with significant demand for safer and more effective treatments.
Patient-Centered Mission
Patients are at the heart of everything we do. Our goal is to make chemotherapy safer, more effective, and less burdensome – for a better quality of life.